Middle East and Africa Prostate Cancer Diagnostics Market – Industry Trends and Forecast to 2028

  • Medical Devices
  • Published Report
  • Mar 2021
  • MEA
  • 350 Pages
  • No of Tables: 123
  • No of Figures: 55

Middle East and Africa Prostate Cancer Diagnostics Market, By Product Type (Instruments, Reagents & Consumables and Accessories), Diagnostics Type (Preliminary Screening Tests, Confirmatory Tests), Age Group (Adult, Pediatric and Geriatrics), Type (Prostatic Adenocarcinoma, Small Cell Carcinoma and Others), Stage (Localized Prostate Cancer, Recurrent/Advanced Prostate Cancer and Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic)), Sample Type (Blood, Tissue, Urine and Others), End User (Independent Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel & Rest of Middle East and Africa) Industry Trends and Forecast to 2028     

Middle East and Africa Prostate Cancer Diagnostics MarketMarket Analysis and Insights: Middle East and Africa Prostate Cancer Diagnostics Market

The prostate cancer diagnostics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.9% in the forecast period of 2021 to 2028 and is expected to reach USD 320.40 million by 2028. Increasing focus on the disease burden and increasing awareness regarding the disease are the major drivers which are propelling the prostate cancer diagnostics market in the forecast period.

The prostate cancer begins when the cells in the prostate gland started to grow at an abnormal pace and the condition is known to be prostate cancer. The prostate is a gland found only in males. It makes some of the fluid that is part of semen. The prostate cancer diagnostics is a technique of detection of cancer mainly in the early stage to conduct the future treatment approach which can increase the survival rate.

The development of prostate cancer is closely linked with the age, with the increasing geriatric population, there is the significant increase in the incidence for prostate cancer. This will increase the demand for the diagnostics product for the detection of the disease and is expected to act as a driver for the prostate cancer diagnostics market. The PSA testing is one of the primary tests that are used for prostate cancer detection. However, the contradictions between the government and medical services provider for using PSA and related test is expected to restraint the prostate cancer diagnostics market. The market have a huge potential to grow and with the entry of new market players trying to enter market using business expansion via distribution agreements and have invested towards the prostate cancer diagnosis is expected to increase the market size and will act as opportunity for the prostate cancer diagnostics market. The barrier related with conducting the cancer diagnostics test may affect the life of the population and this is one of the most difficult part to overcome with respect to the low income countries, thus this is affecting the diagnostics community and acting as a challenge for the prostate cancer diagnostics market.  

The prostate cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the prostate cancer diagnostics market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Prostate Cancer Diagnostics MarketProstate Cancer Diagnostics Market Scope and Market Size

The prostate cancer diagnostics market is categorized into eight notable segments which are based on the product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product type, the prostate cancer diagnostics market is segmented into instruments, reagents & consumables and accessories. In 2021, reagents & consumables segment is dominating in the prostate cancer diagnostics market as it includes the PSA testing products which is the primary test recommended for preliminary testing.
  • On the basis of diagnostics type, the prostate cancer diagnostics market is segmented into preliminary screening tests and confirmatory tests. In 2021, preliminary screening tests segment is dominating in the prostate cancer diagnostics market as the number of preliminary tests surpass the number of confirmatory tests by significant percentage.  
  • On the basis of age group, the prostate cancer diagnostics market is segmented into adult, pediatric and geriatrics. In 2021, geriatrics segment is dominating in the prostate cancer diagnostics market as around 60% of cases are diagnosed in men over 65 year of age.
  • On the basis of type, the prostate cancer diagnostics market is segmented into prostatic adenocarcinoma, small cell carcinoma and others. In 2021, prostatic adenocarcinoma segment dominates the prostate cancer diagnostics market because more than 95 percent of prostate cancers are adenocarcinomas which develop in the gland cells and line of the prostate gland.
  • On the basis of stage, the prostate cancer diagnostics market is segmented into localized prostate cancer, recurrent/advanced prostate cancer and castration-resistant prostate cancer (metastatic and non-metastatic). In 2021, localized prostate cancer segment dominates the prostate cancer diagnostics market as approximately 80 percent to 85 percent of all prostate cancers are detected in the local or regional stages which represent stages I, II and III.
  • On the basis of sample type, the prostate cancer diagnostics market is segmented into blood, tissue, urine and others. In 2021, blood segment is dominating the prostate cancer diagnostics market as blood is the primary sample for the most common preliminary test that is PSA test and due to easy availability of blood, less complex procedure of blood sample collection doesn’t take much time which is expected to dominate the prostate cancer diagnostics market.  
  • On the basis of end users, the prostate cancer diagnostics market is segmented into independent diagnostic laboratories, hospitals, cancer research institutes, clinics, ambulatory surgical centers and others. In 2021, independent diagnostic laboratories segment is dominating the prostate cancer diagnostics market as the segment is specialized in conducting various prostate cancer diagnostics.
  • On the basis of distribution channel, the prostate cancer diagnostics market is segmented into direct tender and retail sales. In 2021, direct tender segment dominates the prostate cancer diagnostics market as they are the primary source of procurement of reagents, consumables, devices and accessories by healthcare organizations and diagnostic labs.

Prostate Cancer Diagnostics Market Country Level Analysis

The prostate cancer diagnostics market is analysed and market size information is provided by the country, product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel as referenced above.

The countries covered in the prostate cancer diagnostics market report are the South Africa, Saudi Arabia, UAE, Egypt, Israel & Rest of Middle East and Africa.

South Africa is expected to grow in the forecast period of 2021 to 2028 due to increasing focus on prostate cancer diagnostics products and rising awareness about it.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by manufactures is Creating New Opportunities for Players in the Prostate Cancer Diagnostics Market 

The prostate cancer diagnostics market also provides you with detailed market analysis for every country growth in prostate cancer diagnostics product sales, impact of advancement in the prostate cancer diagnostics and changes in regulatory scenarios with their support for the prostate cancer diagnostics market. The data is available for historic period 2010 to 2019. 

Competitive Landscape and Prostate Cancer Diagnostics Market Share Analysis

The prostate cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to prostate cancer diagnostics market.  

The major companies providing prostate cancer diagnostics market are F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc., HUMASIS, Teco Diagnostics, Hologic Inc., Accuquik Test Kits, MDxHealthcare, Abbott, Siemens Healthcare GmbH, OPKO Health Inc., Myraid Genetics, Inc., DiaSorin S.p.A, Beckman Coulter, Inc. (a subsidiary of Danaher), Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation), bioMérieux SA, Metamark Genetics, Inc., Prostatype Genomics, Fujirebio, Proteomedix, Eurolyser Diagnostica GmbH among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the prostate cancer diagnostics market.

For instance,  

  • In January 2021, Hologic Inc. announced that they have agreed to acquire SOMATEX, Inc., for USD 64 million. This company is the provider of Biomarkers for cancer. After the complete acquisition, Hologic Inc. will take a jump start in global oncology biomarker and will expand the company product portfolio for cancer patients and will add up to the company’s future sales and revenue.
  • In August 2020, HUMASIS announced that they have passed the preliminary examination for listing by the Korea Exchange last month after undergoing a technical evaluation process by a professional evaluation agency in November last year and is soon to be get n approval for the listing in Korean stock exchange. This will be an achievement for the company and will boost the company in future business expansion and business strategies.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the prostate cancer diagnostics market which also provides the benefit for organisation to improve their offering for prostate cancer diagnostics market.   

Customization Available: Middle East and Africa Prostate Cancer Diagnostics Market  

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.  


SKU-

LIST OF TABLES

TABLE 1 CATEGORIZATION UNDER THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA '88) OF 1988

TABLE 2 AGE AND PROBABILITY OF DEVELOPING PROSTATE CANCER

TABLE 3 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 2019-2028 (UNITS)

TABLE 5 MIDDLE EAST AND AFRICA REAGENTS & CONSUMABLES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA INSTRUMENTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA ACCESSORIES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA CONFIRMATORY TESTSIN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA PROSTATIC ADENOCARCINOMAS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 13 MIDDLE EAST AND AFRICA SMALL CELL CARCINOMA IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA GERIATRICS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA SEVERE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA SEVERE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA LOCALIZED PROSTATE CANCER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA RECURRENT/ADVANCED PROSTATE CANCER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA BLOOD IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA TISSUE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA URINE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA HOSPITALS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA CLINICS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA CANCER RESEARCH INSTITUTES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA DIRECT TENDER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA HOSPITALS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 41 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 53 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 54 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 55 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 56 SOUTH AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 57 SOUTH AFRICA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 58 SOUTH AFRICA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 59 SOUTH AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 60 SOUTH AFRICA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 61 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 62 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 64 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 65 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 66 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 67 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 68 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 69 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 70 SAUDI ARABIA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 71 SAUDI ARABIA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 72 SAUDI ARABIA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 73 SAUDI ARABIA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 74 SAUDI ARABIA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 75 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 76 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 78 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 79 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 80 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 81 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 82 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 83 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 84 UAE PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 85 UAE CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 86 UAE IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 87 UAE MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 88 UAE BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 89 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 90 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 92 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 93 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 94 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 96 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 97 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 98 ISRAEL PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 99 ISRAEL CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 100 ISRAEL IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 101 ISRAEL MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 102 ISRAEL BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 103 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 104 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 106 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 107 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 108 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 109 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 110 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 111 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 112 EGYPT PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 113 EGYPT CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 114 EGYPT IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 115 EGYPT MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 116 EGYPT BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 117 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 118 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 119 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 120 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 121 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 122 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 123 REST OF MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions